Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland

Scandinavian Journal of Primary Health Care

Volumn 28, Issue 4, 2010, Pages 237-241

  Virjo, Irma ^a   Mäkelä, Kari ^a   Aho, Juhani ^b   Kalliola, Pentti ^c   Kurunmäki, Harri ^d   Uusitalo, Leena ^e   Valli, Markku ^f   Ylinen, Suvi ^g  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Jalasjärvi Health Centre   (Finland)

^c Lapua Health Centre   (Finland)

^d Kurikka Health Centre   (Finland)

^e Health Centre of Lake Ostrobothnia   (Finland)

^f Health Centre of Seinäjoki   (Finland)

^g Inter Municipal Health Centre of Kuusiokunnat   (Finland)

Author keywords

Anticoagulation treatment; Atrial fibrillation; General practice; Prevalence; Primary health care; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; FINLAND; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; WARFARIN;

EID: 78649257734     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.3109/02813432.2010.514138     Document Type: Conference Paper

References (20)

1. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology. Foundation guide to warfarin therapy. Circulation 2003;107:1692-1711.
2. Eskola K, Aittoniemi P, Kurunmäki H, Latva-Nevala A, Paloneva M, Wallin A-M, Viitaniemi M, Virjo I, Ylinen S, Öhman S, Isokoski M. Anticoagulant treatment in primary health care in Finland. Scand J Prim Health Care 1996;14:165-70.
3. Viitaniemi M, Eskola K, Kurunmäki H, Latva-Nevala A, Wallin A-M, Paloneva M, Virjo I, Ylinen S, Öhman S, Isokoski M. Anticoagulant treatment of patients with atrial fi brillation in primary health care. Scand J Prim Health Care 1999;17:59-63.
4. Wändell PE Anticoagulant patients in Swedish primary health care: A comparison 5 years apart. Scan J Prim Health Care. 1998, 16; 183-7.
5. Nilsson GH, Bj ö rholt I, Krakau I. Anticoagulant treatment of patients with chronic atrial fi brillation in primary health care in Sweden: A retrospective study of incidence and quality in a registered population. BMC Fam Pract 2004;21: 612-6.
6. Nilsson GH, Bj ö rholt I. Occurrence and quality of anticoagulant treatment of chronic atrial fi brillation in primary health care in Sweden: A retrospective study on electronic patient records. BMC Clin Pharmacol 2004;4:1.
7. Aromaa A, Heli ö vaara M, Impivaara O, Knekt P, Maatela J, Joukamaa M. Terveys, toimintakyky ja hoidontarve Suomessa. Mini-Suomi terveystutkimuksen perustulokset [Health, functional limitations and need of care in Finland. Basic results from the Mini-Finland Health Survey]. English summary, AL:32. Helsinki and Turku, Finland: Publications of Social Insurance Institution; 1989.
8. Käypähoito-suositu S. Suomen Kardiologisen Seuran aset-tama ty ö ryhm ä. Eteisv ä rin ä (Current care guidelines: Working group set up by the Finnish Cardiac Society. Atrial fi brillation). Duodecim. 2005, 121; 2470-94.
9. Atrial fi brillation. Current care summary. Working group set up by the Finnish Cardiac Society. http://www.kaypahoito.fi/kotisivut/sivut.koti?p- sivusto=6&p-navi = 1303&p-url=http://www.kaypahoito.fi/kh/kh-julkaisu. suositukset (accessed 21 January 2009).
10. Petursson H, Linn G, Sigurdsson JA, Hetlevik I. Current European guidelines for management of arterial hypertension: Are they adequate for use in primary care? Modelling study based on the Norwegian HUNT 2 population. BMC Fam Pract 2009;10:70.
11. Ansell J, Jakobson A, Levy J, V ö ller H, Hasenkam J. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005;99:37-45.
12. Lamminen H, Niiranen S, Niemi K, Mattila H, Kalli S. Personal health care and the new media in anticoagulant treatment. Scan J Prim Health Care 2002;20:123-5.
13. Berry C, Norrie J, McMurray JJ. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke: An imputed placebo analysis. Cardiovasc Drugs Ther 2005;19:149-51.
14. Weitz JI, Hirsh J, Samama MM; American College of Chest Physicians. Chest 2008;133(6 Suppl):234S-256S
15. Erratum in: Chest 2008;134:473.
16. Rosencher N, Arnaout L, Chabbouh T, Bellamy L. [Rivar-oxaban (Xarelto): effi cacy and safety]. Ann Fr Anesth Reanim 2008;(Suppl 3):S22-7. Review. In French.
17. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med 2009;361:1139-51.
18. Wallvik J, Sj ä lander A, Johansson L, Bjuhr Ö, Jansson J-H. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care 2007;25: 123-8
19. Population projection 2007-2040. Source: Population and cause of death statistics. Statistics Finland. http://www.stat. fi/til/vaenn/2007/vaenn-2007- 2007-05-31-tie-001-en.html
20. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TSM. Secular trends in incidence of atrial fi brillation in Olmsted County, Mnnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25.